CD94 Is Essential for NK Cell-Mediated Resistance to a Lethal Viral Disease
It is well established that natural killer (NK) cells confer resistance to many viral diseases, but in only a few instances the molecular mechanisms whereby NK cells recognize virus-infected cells are known. Here we show that CD94, a molecule preferentially expressed by NK cells, is essential for th...
Saved in:
Published in: | Immunity (Cambridge, Mass.) Vol. 34; no. 4; pp. 579 - 589 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Elsevier Inc
22-04-2011
Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | It is well established that natural killer (NK) cells confer resistance to many viral diseases, but in only a few instances the molecular mechanisms whereby NK cells recognize virus-infected cells are known. Here we show that CD94, a molecule preferentially expressed by NK cells, is essential for the resistance of C57BL/6 mice to mousepox, a disease caused by the
Orthopoxvirus ectromelia virus. Ectromelia virus-infected cells expressing the major histocompatibility complex (MHC) class Ib molecule Qa-1
b are specifically recognized by the activating receptor formed by CD94 and NKG2E. Because CD94-NKG2 receptors and their ligands are highly conserved in rodents and humans, a similar mechanism may exist during human infections with the smallpox and monkeypox viruses, which are highly homologous to ectromelia virus.
[Display omitted]
► Deficiency in CD94 results in susceptibility to lethal mousepox ► NK cells require CD94 to protect from mousepox ► CD94-NKG2E recognizes ECTV-infected cells in a Qa-1
b-dependent manner |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 L.J.S. and L.L.L. are both senior authors L.J.S. and L.L.L. conceived the initial idea; M.F. performed most of the experiments; L.J.S. supervised the project; M.O. generated some of the reporter cells; P.S. and T.E. produced the CD94 blocking mAb; L.J.S and L.L.L., contributed reagents and analytic tools; M.F., M.O., L.L.L., and L.J.S. discussed the general design and the analysis of experiments; M.F. and L.J.S. designed most of the experiments; L.J.S. wrote the manuscript with M.F. collaboration; M.F. and L.J.S. prepared the figures. L.J.S. and L.L.L. should be considered senior authors. All the authors approved the final manuscript. Author contributions |
ISSN: | 1074-7613 1097-4180 |
DOI: | 10.1016/j.immuni.2011.02.015 |